Rheumatoid arthritis (RA) is associated with increased cardiovascular mortality and morbidity [1,2]. Most studies among RA patients were performed in an era in which RA could only be suboptimally managed. With current available therapeutics for RA and treatment guidelines aiming at remission in a relatively short time, we assume that the cardiovascular risk (CVR) will be lower because of the shorter duration of systemic inflammation.[3]
